Clinical trials: Polymyalgia Rheumatics (PMR)
Polymyalgia Rheumatica (PMR)
Justification And Evaluation of Baricitinib Plus Corticosteroids Versus corticosteroiDs Alone in pOlymyalgia RhEumatica
Polymyalgia rheumatic (PMR) is an inflammatory rheumatic disease affecting the elderly. The diagnosis is based on established ACR/EULAR classification criteria.
- Trial name
- JADORE-BARI (NCT07279688)
- Testing
- Baricitinib 4 MG Oral Tablet, Baricitinib 2 MG Oral Tablet
- Where
- 23 sites in France
- Volunteers
- 140 people
- Sponsor
- University Hospital, Brest
Giant Cell Arteritis, Polymyalgia Rheumatica
Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Secukinumab in Patients With GCA or PMR
This study will examine how intravenous (i.v.) Secukinumab will be processed in the body (pharmacokinetics [PK]) and whether it will be safe and tolerable after multiple doses of i.v.
- Trial name
- NCT06130540
- Testing
- Secukinumab
- Where
- 19 sites in United States, Czechia and 4 more
- Volunteers
- 65 people
- Sponsor
- Novartis Pharmaceuticals
Ankylosing Spondylitis (AS), Psoriatic Arthritis (PsA)
A Registry Study Assessing PRO, Dosing Patterns, and Safety of Vunakizumab in Patients With General Rheumatic Diseases.
Ankylosing spondylitis, radiographically negative axial spondyloarthritis, psoriatic arthritis, polymyalgia rheumatica, Takayasu arteritis, giant cell arteritis, non-ocular Behcet's disease, and enthesitis-related arthritis are…
- Conditions
- Ankylosing Spondylitis (AS), Psoriatic Arthritis (PsA), Nr-axSpA, Polymyalgia Rheumatica (PMR)
- Trial name
- V-MIRACLE (NCT06766552)
- Where
- China
- Volunteers
- 10,000 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Polymyalgia Rheumatica
A Study Assessing the Efficacy and Safety of Lodotra® Compared to Prednisone IR in Subjects Suffering From PMR
The study compares the efficacy and safety of modified release prednisone versus immediate release prednisone in patients suffering from polymyalgia rheumatica.
- Trial name
- NCT01821040
- Testing
- Lodotra®, Prednisone IR (immediate release)
- Where
- United Kingdom
- Volunteers
- 62 people
- Sponsor
- Mundipharma Research Limited
Adrenal Insufficiency, Polymyalgia Rheumatica (PMR)
Hydrocortisone and Placebo in Patients With Symptoms of Adrenal Insufficiency After Cessation of Glucocorticoid Treatment
Cortisol, a glucocorticoid (GC) hormone secreted from the adrenal glands, is essential for survival. Cortisol also possesses anti-inflammatory actions and GC formulations (prednisolone) are used to treat many inflammatory…
- Conditions
- Adrenal Insufficiency, Polymyalgia Rheumatica (PMR), Giant Cell Arteritis (GCA)
- Trial name
- REPLACE (NCT05193396)
- Testing
- Hydrocortisone
- Where
- 3 sites in Denmark
- Volunteers
- 100 people
- Sponsor
- Marianne Andersen
Polymyalgia Rheumatica
Rituximab Effect on Decreasing glUcoCorticoid Exposition in PolyMyalgia Rheumatica Patients Experiencing a PMR Relapse
Polymyalgia rheumatica (PMR) is prevalent among elderly. Untreated, it leads to major reduction in quality of life. Glucocorticoids are the cornerstone of treatment, but have drawbacks, warranting glucocorticoid sparing…
- Trial name
- REDUCE-PMR-2 (NCT05533164)
- Testing
- Rituximab
- Where
- Netherlands
- Volunteers
- 174 people
- Sponsor
- Sint Maartenskliniek
Giant Cell Arteritis, Polymyalgia Rheumatica
DANIsh VASculitis Database (DANIVAS)
The aim of this national pragmatic observational study is to investigate whether the use of new diagnostic imaging modalities facilitates disease stratification that can potentially predict treatment response, relapse risk and…
- Trial name
- DANIVAS (NCT05935709)
- Where
- 2 sites in Denmark
- Volunteers
- 3,000 people
- Sponsor
- Aarhus University Hospital
Polymyalgia Rheumatica
A Trial of Prednisolone in Combination With SPI-62 or Placebo in Subjects With Polymyalgia Rheumatica (PMR)
This will be a single-blind, placebo-controlled phase 2 trial to compare prednisolone effects with and without SPI-62 in participants with PMR.
- Trial name
- NCT05436652
- Testing
- SPI-62, Prednisolone 10mg, Additional prednisolone
- Where
- 10 sites in Germany, Poland
- Volunteers
- 66 people
- Sponsor
- Sparrow Pharmaceuticals
Polymyalgia Rheumatica (PMR)
Using Personalized Rehabilitation to Reduce Disease and Increase Activity of Patients With Polymyalgia Rheumatica
Polymyalgia rheumatica (PMR) is a condition that causes joint pain and stiffness, making it hard for people to do everyday tasks.
- Trial name
- NCT07749547
- Testing
- Movement Pattern Training (MoveTrain), Usual Care
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Washington University School of Medicine
Polymyalgia Rheumatics (PMR)
Efficacy and Safety of Ivarmacitinib in the Treatment of Patients With Polymyalgia Rheumatica
The study intends to explore the efficacy and safety of Ivarmacitinib in therapy for polymyalgia rheumatica through a multicenter, randomized, double-blind, placebo-controlled study, and to explore the effectiveness of…
- Trial name
- NCT07266168
- Testing
- Ivarmacitinib tablet
- Volunteers
- 80 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Giant Cell Arteritis (GCA), Polymyalgia Rheumatica (PMR)
Pilot Study to evaluateThrombomodulin to Rule Out Giant Cell Arteritis (GCA) in Polymyalgia Rheumatica (PMR) Patients. (THROPIQ)
Polymyalgia rheumatica (PMR) is a rheumatologic condition occurring in patients > 50 years old, characterized by inflammatory pain of the scapular (shoulder) and pelvic (hip) girdles.
- Trial name
- THROPIQ (NCT06609668)
- Testing
- Additional blood samples
- Where
- France
- Volunteers
- 78 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Polymyalgia Rheumatica (PMR)
Using Novel Imaging to Rethink Diagnostic and Treatment Strategies for Polymyalgia Rheumatica
Polymyalgia rheumatica (PMR) is the most common chronic inflammatory rheumatic disease among the elderly and is characterized by proximal extremity pain and fatigue.
- Trial name
- REMAP PMR (NCT07010484)
- Testing
- PET/MRI, PET/CT with 18-FDG
- Where
- 7 sites in Denmark
- Volunteers
- 149 people
- Sponsor
- Kresten Krarup Keller
Polymyalgia Rheumatica
Timed Release Tablet Prednisone in Polymyalgia Rheumatica
Polymyalgia Rheumatica (PMR) is a disease that usually affects older people. Patients complain of stiffness and pain around the shoulders and hips. The stiffness is more severe in the morning.
- Trial name
- NCT00836810
- Testing
- Timed Release Tablet Prednisone, Prednisolone
- Where
- United Kingdom
- Volunteers
- 12 people
- Sponsor
- University Hospitals Bristol and Weston NHS Foundation Trust
Polymyalgia Rheumatica
Delayed Release Prednisone in PMR
A four-week, randomized, controlled, open-label trial of DR prednisone in which patients receive in period 1 one of three-night time doses of treatment (4mg, 7mg or 10mg) for two weeks followed in period 2 by treatment with 15mg…
- Trial name
- NCT02702778
- Testing
- Delayed-Release (DR) Prednisone, Immediate Release (IR) Prednisone
- Where
- 6 sites in United States
- Volunteers
- 8 people
- Sponsor
- Dinora, Inc.
Polymyalgia Rheumatica (PMR)
Study of Tocilizumab to Treat Polymyalgia Rheumatica
This is a fifteen-month open label, Phase IIa clinical trial is being conducted to assess the tolerability, safety and efficacy of a medication called Tocilizumab (Actemra®) in patients with polymyalgia rheumatica (PMR).
- Trial name
- NCT01396317
- Testing
- Tocilizumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Hospital for Special Surgery, New York
Polymyalgia Rheumatica
Validation of the PMR Activity Score and Evolution of Patient-reported Outcomes in Patients With Polymyalgia Rheumatica
Polymyalgia rheumatica (PMR) is a systemic inflammatory disease that affects elderly people. It is characterized by pain and morning stiffness in the shoulders, pelvic girdles and neck.
- Trial name
- NCT05542316
- Where
- Belgium
- Volunteers
- 133 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Giant Cell Arteritis (GCA), Polymyalgia Rheumatica (PMR)
AYLo - AutoimmunitY and Loss of y
The AYLo study (AutoimmunitY and Loss of y - Investigating the Role of Hematopoietic Mutations and Mosaic Mutation in the Y Chromosome in Autoimmune Rheumatologic Diseases) aims to systematically investigate hematopoietic…
- Conditions
- Giant Cell Arteritis (GCA), Polymyalgia Rheumatica (PMR), ANCA Associated Vasculitis (AAV), Idiopathic Inflammatory Myopathies
- Trial name
- AYLo (NCT06696027)
- Testing
- Single nucleotide polymorphisms (SNP), 3'mRNA sequencing, Enzyme-linked immunosorbent assay (ELISA) and Legendplex Array
- Where
- Germany
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- University of Bonn
Polymyalgia Rheumatica
Treatment With Leflunomide in Patients With Polymyalgia Rheumatica
Over the last decades outcome has greatly improved for rheumatoid arthritis (RA) and spondyloarthritis (SpA). This is in sharp contrast to the situation for polymyalgia rheumatica (PMR), with a lifetime prevalence of 2.4% for…
- Trial name
- PMRLEFRCT (NCT03576794)
- Testing
- Leflunomide 20 mg, Prednisolone
- Where
- 2 sites in Netherlands
- Volunteers
- 94 people
- Sponsor
- Elisabeth Brouwer
Polymyalgia Rheumatica
Abatacept in earLy Onset Polymyalgia Rheumatica: Study ALORS
Polymyalgia rheumatic (PMR) is a frequent inflammatory disease. It affects the elderly, with peak incidences at the age of 70 to 80 years; an age >50 years or older, is considered a criterion for the diagnosis.
- Trial name
- ALORS (NCT03632187)
- Testing
- Abatacept
- Where
- 5 sites in France
- Volunteers
- 34 people
- Sponsor
- University Hospital, Brest
Polymyalgia Rheumatica
Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)
The purpose of this extension study is to assess the safety and tolerability of secukinumab when administered long-term in patients with polymyalgia rheumatica.
- Trial name
- REPLENISH-EXT (NCT06331312)
- Testing
- Secukinumab
- Where
- 85 sites in United States, Argentina and 20 more
- Volunteers
- 162 people
- Sponsor
- Novartis Pharmaceuticals